A topical rectal douche product containing Q-Griffithsin does not disrupt the epithelial border or alter CD4
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 05 2023
09 05 2023
Historique:
received:
13
12
2022
accepted:
24
04
2023
medline:
11
5
2023
pubmed:
10
5
2023
entrez:
10
5
2023
Statut:
epublish
Résumé
To reduce HIV transmission, locally applied pre-exposure prophylaxis (PrEP) products for anorectal use will be important complements to oral and injectable PrEP products already available. It is critical to preserve an intact rectal epithelium and avoid an influx of mucosal HIV target cells with such product use. In this phase 1 clinical trial, we evaluated application of a topical rectal douche product containing Q-Griffithsin (Q-GRFT). Colorectal tissue samples were obtained via sigmoidoscopy at baseline, 1 and 24 h after single-dose exposure in 15 healthy volunteers. In situ staining for epithelial junction markers and CD4
Identifiants
pubmed: 37161022
doi: 10.1038/s41598-023-34107-w
pii: 10.1038/s41598-023-34107-w
pmc: PMC10169179
doi:
Substances chimiques
q-griffithsin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
7547Subventions
Organisme : NIH HHS
ID : U19AI113182
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
J Biotechnol. 2020 Aug 20;320:74-76
pubmed: 32553533
Elife. 2015 Feb 03;4:
pubmed: 25647729
J Infect Dis. 2001 Aug 15;184(4):418-28
pubmed: 11471099
Tissue Barriers. 2021 Oct 2;9(4):1943274
pubmed: 34241579
Nat Methods. 2019 Dec;16(12):1226-1232
pubmed: 31570887
AIDS Behav. 2017 Dec;21(12):3336-3345
pubmed: 29119473
Front Cell Infect Microbiol. 2022 Oct 18;12:976033
pubmed: 36329822
AIDS Res Hum Retroviruses. 2015 Nov;31(11):1098-108
pubmed: 26227279
Nat Commun. 2018 Sep 24;9(1):3881
pubmed: 30250170
PLoS Pathog. 2017 Jul 11;13(7):e1006492
pubmed: 28700681
Nat Rev Immunol. 2008 Jun;8(6):447-57
pubmed: 18469831
AIDS Res Hum Retroviruses. 2022 Apr;38(4):279-287
pubmed: 34541872
Curr Opin Immunol. 1993 Apr;5(2):247-52
pubmed: 8507401
J Int AIDS Soc. 2019 May;22(5):e25300
pubmed: 31144462
Infect Immun. 2021 Apr 16;89(5):
pubmed: 33558324
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6099-104
pubmed: 19332801
Sci Rep. 2018 May 23;8(1):8059
pubmed: 29795295
PLoS One. 2022 Jan 20;17(1):e0261775
pubmed: 35051209
Viruses. 2016 Oct 24;8(10):
pubmed: 27783038
Microbiol Spectr. 2021 Oct 31;9(2):e0095721
pubmed: 34494857
AAPS PharmSciTech. 2021 Feb 24;22(3):83
pubmed: 33625602
Sci Rep. 2019 Dec 2;9(1):18120
pubmed: 31792342
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1487-95
pubmed: 23885722
Mar Drugs. 2021 Jul 26;19(8):
pubmed: 34436255
AIDS Behav. 2020 May;24(5):1414-1421
pubmed: 31473846
ACS Infect Dis. 2022 Jul 8;8(7):1253-1264
pubmed: 35426678
BMC Bioinformatics. 2021 Sep 10;22(1):433
pubmed: 34507520
Mar Drugs. 2019 Oct 06;17(10):
pubmed: 31590428
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32229493
AIDS Res Hum Retroviruses. 2017 Aug;33(8):820-826
pubmed: 28296471
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
AIDS. 2014 Jun 19;28(10):1509-19
pubmed: 24809629
Nature. 2010 Mar 11;464(7286):217-23
pubmed: 20220840
J Infect Dis. 2009 Aug 15;200(4):599-608
pubmed: 19586414
Antimicrob Agents Chemother. 2011 Nov;55(11):5159-67
pubmed: 21896910
AIDS Res Hum Retroviruses. 2014 Mar;30(3):241-9
pubmed: 24134315
N Engl J Med. 2008 Jul 31;359(5):463-72
pubmed: 18669425
Immunol Rev. 1997 Apr;156:145-66
pubmed: 9176706
Plant Biotechnol J. 2015 Oct;13(8):1160-8
pubmed: 26176205